Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
  • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N5/00—Radiation therapy
  • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
  • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy

Definitions

• the field of the invention is cancer radiotherapy.
• Radiotherapy and chemotherapy protocols utilized in the treatment of cancer can clearly benefit patients, but can be ineffective or less effective with some cancers.
• both radiotherapy and chemotherapy are associated with significant side effects, including nausea, weight loss, hair loss, damage to the gastrointestinal tract, and skin irritation.
• Mitigation of the side effects of chemotherapy are generally directed at providing symptomatic relief.
• antiemetics can be used to reduce nausea, along with diet modification and eating small, frequent meals that avoid certain foods.
• chemotherapeutic agents are selected to have reduced toxicity in order to reduce side effects, however such agents may also have reduced effectiveness against tumor cells.
• the inventive subject matter provides apparatus, systems and methods in which a nutritional supplement as shown in Table 1 is used in combination with radiotherapy to treat a tumor and/or reduce or eliminate negative side effects of cancer radiotherapy.
• One embodiment of the inventive concept is a method of treating a tumor that includes applying a radiotherapy protocol to a patient in need of treatment and providing the patient with a nutritional supplement formulated as listed in Table 1, where the nutritional supplement is provided in an amount that provides a synergistic effect in reducing tumor volume or weight.
• the method of claim 1 wherein the nutritional supplement is provided to the patient prior to the initiation of radiotherapy.
• Another embodiment of the inventive concept is a method of reducing side effects of radiotherapy that includes applying a radiotherapy protocol to a patient in need of treatment and providing the patient with a nutritional supplement formulated as shown in Table 1, in an amount that is effective to reduce a side effect of the radiotherapy protocol.
• the nutritional supplement is provided to the patient prior to the initiation of radiotherapy.
• Another embodiment of the inventive concept is a method of modulating gene expression in a tumor by providing a nutritional supplement formulated as shown in Table 1 to a tumor or an animal having a tumor, where the nutritional supplement comprises a plurality of components as and is provided in an amount sufficient to modulate expression of a gene of the tumor.
• the nutritional supplement can be provided prior to the initiation of a radiotherapy protocol and/or during the application of radiotherapy.
• the gene encodes for an angiogenesis factor.
• the gene encodes for an apoptosis factor.
• Another embodiment of the inventive concept is a method of reducing metastasis from a tumor by providing a patient having a metastatic tumor with a nutritional supplement formulated as in Table 1, where the nutritional supplement is provided in an amount to reduce metastatic activity of the tumor.
• the nutritional supplement can be provided prior to and/or concurrently with radiotherapy.
• Another embodiment of the inventive concept is a method of reducing angiogenesis in a tumor by providing a patient having a tumor with a nutritional supplement formulated as shown in Table 1, where the nutritional supplement is provided in an amount to reduce an angiogenic activity of the tumor.
• the nutritional supplement can be provided prior to or concurrently with radiotherapy.
• Another embodiment of the inventive concept is a method of reducing growth of a cancer stem cell by providing a patient having a tumor that includes the cancer stem cell with a nutritional supplement formulated as in Table 1, where the nutritional supplement is provided in an amount to reduce growth of the cancer stem cell.
• the nutritional supplement can be provided prior to or concurrently with radiotherapy.
• FIG. 1 depicts a typical treatment protocol, where nutritional supplementation is provided starting either 7 days prior to implementation of radiotherapy or simultaneously with tumor cell implantation. In this study mice were sacrificed 21 days after tumor cell implantation.
• FIGs. 2A and 2B show changes in body weight observed during a treatment protocol as in FIG. 1.
• FIG. 2B provides a histogram of results from a similar study.
• FIGs. 3A to 3D show synergistic effects observed on tumor volume and weight in mice treated with radiotherapy and a nutritional supplement of the inventive concept.
• FIG. 3A shows tumor volume over 21 days.
• FIG. 3B shows tumor volume on days 7 to 11.
• FIG. 3C shows tumor weight following different treatment regimes. Statistically significant differences are indicated (* to ***).
• FIG. 3D provides photographs of tumors excised from mice following treatment with different regimes.
• FIGs. 4 A to 4E show the degree of common radiotherapy side effects related to muscle mass and organ weight in mice treated with radiotherapy alone, a nutritional supplement of the inventive concept, and combined therapy. Statistically significant differences are indicated (* to ***).
• FIG. 4A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on gastrocnemius muscle mass 21 days after tumor cell injection.
• FIG. 4B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on soleus muscle mass 21 days after tumor cell injection.
• FIG. 4C shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on lung (inclusive of metastatic tumor) weight 21 days after tumor cell injection.
• FIG. 4D shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on liver (inclusive of metastatic tumor) weight 21 days after tumor cell injection.
• FIG. 4E shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on spleen (inclusive of metastatic tumor) weight 21 days after tumor cell injection.
• FIGs. 5A to 5G show the degree of common radiotherapy side effects related to various blood cell populations in mice treated with radiotherapy alone, a nutritional supplement of the inventive concept, and combined therapy. Statistically significant differences are indicated (* to ***).
• FIG. 5A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on red blood cell count 21 days after tumor cell injection.
• FIG. 5B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on granulocyte count 21 days after tumor cell injection.
• FIG. 5C shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on platelet count 21 days after tumor cell injection.
• FIG. 5A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on red blood cell count 21 days after tumor cell injection.
• FIG. 5B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on granulocyte count 21 days after tumor cell injection.
• FIG. 5D shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on white blood cell count 21 days after tumor cell injection.
• FIG. 5E shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on lymphocyte count 21 days after tumor cell injection.
• FIG. 5F shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on granulocyte count 21 days after tumor cell injection.
• FIG. 5G shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on neutrophil/lymphocyte percentage ratio 21 days after tumor cell injection.
• FIGs. 6A to 6G show the degree of common radiotherapy side effects related to serum biochemistry, kidney function, and liver function in mice treated with radiotherapy alone or radiotherapy, a nutritional supplement of the inventive concept, and combined therapy. Statistically significant differences are indicated (* to ***).
• FIG. 6A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum albumin 21 days after tumor cell injection.
• FIG. 6B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum creatinine 21 days after tumor cell injection.
• FIG. 6C shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on blood urea nitrogen 21 days after tumor cell injection.
• FIG. 6D shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on total bilirubin 21 days after tumor cell injection.
• FIG. 6E shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum glutamic oxaloacetic transaminase 21 days after tumor cell injection.
• FIG. 6F shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum glutamic-pyruvic transaminase 21 days after tumor cell injection.
• FIG. 6G shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum glucose 21 days after tumor cell injection.
• FIG.s 7A and 7B show the effect of treatment with a nutritional supplement of the inventive concept on inflammation that is associated with tumor growth and with radiotherapy. Mice were treated with radiotherapy alone, a nutritional supplement of the inventive concept, or combined therapy. Statistically significant differences are indicated (* to ***).
• FIG. 7A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum IL-6 21 days after tumor cell injection.
• FIG. 7B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum IL- ⁇ 21 days after tumor cell injection.
• FIGS. 8A to 8G show the effect of treatment with a nutritional supplement of the inventive concept on gene expression in tissue and in tumor cells. Mice were treated with radiotherapy alone, a nutritional supplement of the inventive concept, or combined therapy. Statistically significant differences are indicated (* to ***).
• FIG. 8A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the VEGF gene in an implanted tumor 21 days after tumor cell injection.
• FIG. 8B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the BAX gene in an implanted tumor 21 days after tumor cell injection.
• FIG. 8A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the BAX gene in an implanted tumor 21 days after tumor cell injection.
• FIG. 8C shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the Bcl-2 gene in an implanted tumor 21 days after tumor cell injection.
• FIG. 8D shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the caspase 3 gene in an implanted tumor 21 days after tumor cell injection.
• FIG. 8E shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the BAX gene in lung 21 days after tumor cell injection.
• FIG. 8F shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the Bcl-2 gene in lung 21 days after tumor cell injection.
• FIG. 8G shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the caspase 3 gene in lung 21 days after tumor cell injection.
• FIG. 9 depicts an alternative treatment/study protocol.
• FIG. 9 depicts a treatment/study protocol in which mice receive radiotherapy on days 8, 10, and 12, with nutritional supplementation beginning with the initiation of radiotherapy. Mice are sacrificed at day 14 or at day 24 following implantation of tumor cells.
• FIGs. 1 OA to IOC show results of serum albumin and blood cell population studies performed on mice treated with the protocol shown in FIG. 9. Statistically significant differences are indicated (* to ***).
• FIG. 10A shows serum albumin concentration at 14 days and 24 days following tumor cell implantation in mice treated as shown in FIG. 9.
• FIG. 10B shows lymphocyte counts at 14 days and 24 days following tumor cell implantation in mice treated as shown in FIG. 9.
• FIG. IOC shows N/L Ratios at 14 days and 24 days following tumor cell implantation in mice treated as shown in FIG. 9.
• FIGs. 11A to 11D show results of studies of expression of tumor markers and studies of tumor metastatis performed on mice treated with the protocol shown in FIG. 9.
• FIG. 11 A shows the results of immunofluorescence studies of VEGF expression within a tumor mass 24 days following tumor cell implantation in mice treated as shown in FIG. 9.
• FITC represents VEGF-specific staining.
• FIG. 11B shows the results of immunofluorescence studies of VEGF expression within the lung (metastasis) 24 days following tumor cell implantation in mice treated as shown in FIG. 9.
• FITC represents VEGF-specific staining.
• 11D shows the results of immunofluorescence studies of EGFR expression within the tumor mass 24 days following tumor cell implantation in mice treated as shown in FIG. 9.
• FITC represents EGFR- specific staining in mice treated as shown in FIG. 9.
• FITC represents CD31-specific staining.
• FIG. 12 shows results of studies of cancer stem cell distribution performed on mice treated with the protocol shown in FIG. 9. Immunofluorescence was used to visualize CD31 (a cancer stem cell marker) expression within the tumor mass and in lung tissue
• FIG. 13 shows results of studies of the degree of hypoxia in primary and metastatic tumor sites performed on mice treated with the protocol shown in FIG. 9.
• HlFl-a a hypoxia marker
• FITC represents HlFl-a -specific staining.
• FIG. 14 shows results of qPCR studies of apoptosis marker expression in tumors, performed on mice treated with the protocol shown in FIG. 9. Studies were performed 24 days after tumor cell implantation.
• FIG. 15 depicts an alternative treatment/study protocol.
• FIG. 15 depicts a treatment/study protocol in which mice receive radiotherapy on days 8, 10, and 12, with nutritional supplementation provided prior to tumor cell implantation, at the time of tumor cell implantation, or at the initiation of radiotherapy. Mice are sacrificed at day 21 following implantation of tumor cells.
• FIG. 16 shows photomicrographs of gut cellular architecture in mice treated with the protocol shown in FIG. 15.
• FIGs. 17A to 17F depicts results from studies of gene expression in tumor cells of mice treated with the protocol shown in FIG.15. Statistically significant differences are indicated (* to ***).
• FIG. 17A shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the VEGF gene 21 days after tumor cell injection.
• FIG. 17B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the BAX gene 21 days after tumor cell injection.
• FIG. 17C shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the Bcl-2 gene 21 days after tumor cell injection.
• FIG. 17D shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the Caspase 3 gene 21 days after tumor cell injection.
• FIG. 17E shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the Bcl-2 gene 21 days in lung (i.e.
• FIG. 17F shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on expression of the Caspase 3 gene 21 days in lung (i.e. metastasis) after tumor cell injection.
• FIG. 18 depicts an alternative treatment/study protocol.
• FIG. 18 depicts a treatment/study protocol in which mice receive radiotherapy on days 8, 10, and 12, with nutritional supplementation provided for 7 days prior to tumor cell implantation. Mice are sacrificed at day 24 following implantation of tumor cells.
• FIGs. 19A and 19B show the results of studies of loss of body mass and muscle mass in mice treated with the protocol shown in FIG. 18. Statistically significant differences are indicated (* to ***).
• FIG. 19A shows the effect of treatment with a nutritional supplement of the inventive concept on body mass in mice receiving repeated radiotherapy following tumor cell implantation using the protocol shown in FIG. 18.
• FIG. 19B shows the effect of treatment using radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on gastrocnemius muscle mass 21 days after tumor cell injection using the protocol shown in FIG. 18.
• FIG. 20 depicts an alternative treatment/study protocol.
• FIG. 20 depicts a treatment/study protocol in which mice receive radiotherapy on days 8, 10, and 12, with nutritional supplementation provided for 7 days prior to, the day of, or 8 days after tumor cell implantation. Mice are sacrificed at day 21 following implantation of tumor cells.
• FIG. 21 shows the effect of treatment with a nutritional supplement on body mass in mice receiving repeated radiotherapy following tumor cell implantation using the protocol shown in FIG. 20. Statistically significant differences are indicated (* to ***).
• FIG. 22 shows changes in tumor volume over time on repeated radiotherapy in combination with treatment with a nutritional supplement of the inventive concept in mice treated as in the protocol shown in FIG. 20.
• FIGs. 23 A and 23B show the effect of the treatment protocol shown in FIG. 20 on serum concentration levels of pro -inflammatory cytokines in mice undergoing repeated radiotherapy treatments.
• FIG. 23 A shows the effect of treatment using repeated radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum TNF-a 21 days after tumor cell injection in mice treated using the protocol shown in FIG. 20.
• FIG. 23B shows the effect of treatment using repeated radiotherapy, a nutritional supplement of the inventive concept, and combined treatment on serum IL-6 21 days after tumor cell injection in mice treated using the protocol shown in FIG. 20.
• the inventive subject matter provides compositions and methods in which a nutritional supplement (e.g. NutraWell) is used in combination with radiotherapy.
• a nutritional supplement e.g. NutraWell
• Combination therapy with radiation and a nutritional supplement of the inventive concept surprisingly provides a significant synergistic effect in reduction of tumor size.
• side effects of radiotherapy e.g. neutropenia, loss of body mass, loss of muscle mass, inflammation, damage to acyl cells of the gastrointestinal tract, etc.
• side effects of radiotherapy e.g. neutropenia, loss of body mass, loss of muscle mass, inflammation, damage to acyl cells of the gastrointestinal tract, etc.
• genes related to angiogenesis, proinflammatory cytokines, and apoptosis are modulated.
• metastasis is prevented and the growth and spread of cancer stem cells is reduced.
• the Inventors contemplate that similar benefits can be found in cotherapy with anti-cancer immunotherapy agents and a nutritional supplement of the inventive concept.
• inventive subject matter provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
• a nutritional supplement composition of the inventive concept such as shown in Table 1 (NutrawellTM), is provided to improve the results of radiotherapy.
• Vitamin D3 25 5000 IU
• Vitamin A Acetate 500 100000 IU
• Lact. Acidophilus (app. 10 billion total) 2 500 mg
• Lac. Bulgaricus (app. 10 billion total) 2 500 mg
• composition shown in Table 1 includes components that have various physiological and biochemical effects, including anti-inflammatory activity, lowering of blood glucose levels, lowering of cholesterol, and anti-tumor activity. Other components provide supplementation of necessary vitamins, minerals, and amino acids at elevated levels. Other components (e.g.
• compositions shown in Table 1 also includes certain flavorants (e.g. brown sugar, honey, vanilla flavor and/or masking agent) that serve to improve palatability and acceptance.
• Certain components e.g. honey, brown sugar, milk, rice protein, casein
• honey, brown sugar, milk, rice protein, casein can provide both flavor and caloric energy.
• components of the nutritional supplement are provided as powders and/or granules. Similarly, in preferred embodiments of the inventive concepts components of the nutritional supplement are provided in relative amounts as indicated in Table 1. In some embodiments the components of the nutritional supplement are provided as a single, mixed formulation. In other embodiments components of the nutritional supplement can be provided as a kit or similar assembly containing different components of the formulation segregated or packaged separately (for example, to provide different storage conditions conducive to component stability).
• oils found in the formulation are at least consumer grade, and preferably highly purified (>95% pure).
• mineral components e.g. potassium, calcium, sodium, magnesium iron, manganese
• any safe and absorbable salt e.g. a halide salt, phosphate salt, carbonate salt, sulfate salt
• oxide e.g. gluconate
• organic complex e.g. gluconate
• chromium, molybdenum, selenium are supplied in the form of a yeast component, which can include provision as a yeast-containing powder or suspension and/or as a complex with a peptide or amino acid as a result of metabolism of such metals by yeast.
• preparation of various non-yeast fungi e.g. Cordyceps, Ganoderma Lucidum, Shiitake, Maitake, Turkey Tail
• a nutritional supplement of the inventive concept can be provided in amounts ranging from about 1 mg/kg body weight to about 100 g/kg body as a unit dose. Such a unit dose can be provided on a schedule ranging from 4 times a day to one time per week.
• the nutritional supplement can be provided as one or more pills or capsules.
• the nutritional supplement can be provided as a powder, granular, and/or liquid formulation that is added to a food or a beverage prior to consumption.
• the nutritional supplement can be provided as a food item, such as a food or candy bar.
• the nutritional supplement can be provided as a solution, suspension, or beverage that is suitable for oral consumption and/or provision by tube feeding.
• packaging that excludes light, moisture, and/or oxygen can be used to extend the shelf life of the nutritional supplement.
• a nutritional supplement of the inventive concept can be packaged with a hygroscopic agent (such as silica gel), a non- reactive gas (such as N2 or a noble gas), and/or under vacuum in order to extend shelf life.
• a hygroscopic agent such as silica gel
• a non- reactive gas such as N2 or a noble gas
• under vacuum in order to extend shelf life.
• Such packaging can, for example, provide a nutritional supplement of the inventive concept in single unit doses and additionally provide directions for preparation and/or dosing frequency.
• mice carrying human tumor cells were treated with 1 gram per day of the nutritional supplement, radiotherapy, or 1 gram per day of the nutritional supplement and chemotherapy.
• the mice were weighed during treatment to characterize side effects such as nausea and loss of appetite.
• blood samples were taken to determine values for certain serum and cellular components.
• tumor was determined and the impact of therapy on organ and muscle volume was determined.
• the degree of neutropenia was also characterized.
• a typical set of test groups is shown in Table 2.
• a typical treatment schedule is depicted schematically in FIG. 1.
• nutritional supplementation is provided starting either 7 days prior to implementation of radiotherapy or simultaneously with tumor cell implantation. Mice were sacrificed 21 days after tumor cell implantation.
• mice receiving both radiotherapy and a nutritional supplement of the inventive concept gained weight at a significantly greater rate than those receiving only radiotherapy, indicating a reduction in undesirable side effects normally associated with this treatment mode.
• FIGs. 3A to 3D show typical synergistic effects on tumor volume and weight of co- treatment with radiotherapy and a nutritional supplement of the inventive concept.
• FIG. 3A shows the effect of various treatment protocols on tumor volume over the course of 3 weeks, with FIG. 3B providing an scaled view of the effect over the initial 11 days.
• treatment with the nutritional supplement alone provides an approximately 60% reduction in tumor volume.
• Treatment with radiation alone provides a similar reduction in tumor volume.
• a synergistic effect one would therefore anticipate a reduction in tumor volume to approximately 25% of that of the untreated tumor.
• what is observed is a greater than 90% reduction in tumor volume to approximately 7% of the untreated tumor- indicative of a significant synergistic effect.
• treatment with nutritional supplement of the inventive concept can modify gene expression in tumor cells in vivo, and can provide a synergistic effect to such changes in gene expression resulting from radiotherapy.
• the genes are related to cytokines and/or are related to apoptosis. Examples of the effect of radiotherapy, treatment with nutritional supplement of the inventive concept, and cotherapy on gene expression in implanted tumor cells in vivo are shown in FIG. 8A to 8F. As shown gene expression is (at least to some extent) normalized in tumor cells of mice so treated.
• FIG. 9 shows the protocol shown in FIG. 9 .
• the tumor cells selected for implantation are derived from a lung tumor and have a strong tendency to metastasize to the lung from the implantation site.
• FIGs. 11A to 11D show the results of immunocytochemistry studies of different tissues from mice treated with the protocol shown in FIG. 9. Cell surface markers associated with the tumor cells are notably reduced. It is notable that nutritional supplement of the inventive concept alone can reduce or even eliminate metastasis.
• Treatment with nutritional supplement of the inventive concept, radiotherapy, and combined nutritional supplement of the inventive concept and radiotherapy using the protocol shown in FIG. 9 also has an impact on tumor stem cells.
• the tumor cells selected for implantation are derived from a lung tumor and have a strong tendency to metastasize to the lung from the implantation site.
• FIG. 12 shows the results of
• Treatment with nutritional supplement of the inventive concept, radiotherapy, and combined nutritional supplement of the inventive concept and radiotherapy using the protocol shown in FIG. 9 also has an impact on hypoxia often found in or among tumor cells.
• the tumor cells selected for implantation are derived from a lung tumor and have a strong tendency to metastasize to the lung from the implantation site.
• FIG. 13 shows the results of immunocytochemistry studies of different tissues from mice treated with the protocol shown in FIG. 9.
• treatment with nutritional supplement of the inventive concept in the absence of radiotherapy reduces or eliminates the occurrence of hypoxia markers in both in the tumor implantation site and at the lung metastatic site, and potentiates the effects of radiotherapy when used in combination.
• Treatment with nutritional supplement of the inventive concept, radiotherapy, and combined nutritional supplement of the inventive concept and radiotherapy using the protocol shown in FIG. 9 also has an impact on apoptic activity in tumor cells.
• Results of qPCR studies for expression of apoptosis markers at 24 days from tumor cell implantation in mice are shown in FIG. 14.
• treatment with nutritional supplement of the inventive concept both enhances the effect of radiotherapy and increases expression of apoptosis-related genes in the absence of radiotherapy.
• FIG. 15 Another treatment protocol utilizing multiple rounds of radiotherapy is shown in FIG. 15. Treatment groups resulting from the protocol shown in FIG. 15 are shown in Table 4.
• FIG. 16 shows photomicrographs that demonstrate the effect of supplementation of nutritional supplement of the inventive concept on the cellular architecture of the gut during radiotherapy. As shown, supplementation with NutraWell not only maintains but, surprisingly, can also enhance the intestinal brush border during radiotherapy.
• FIGs. 17A to 17F results from tumor cells that have metastasized from the initial implantation site.
• FIGs. 17E and 17F show results from tumor cells that have metastasized from the initial implantation site.
• expression of VEGF and Bcl-2 are reduced, while Caspase 3 is elevated.
• BAX shows a more complex response, being elevated in animals treated with nutritional supplement of the inventive concept and the elevation suppressed when used in combination with radiotherapy.
• FIG. 18 Another protocol for utilizing provision of nutritional supplement of the inventive concept with radiotherapy is shown in FIG. 18. A summary of the treatment groups generated by the protocol shown in FIG. 18 is provided in Table 5.
• nutritional supplement of the inventive concept is provided 7 days prior to implantation of tumor cells, with radiotherapy taking place on days 8, 10, and 12 following implantation. Mice were sacrificed on day 24 following implantation.
• Such a protocol was used to evaluate the effects of the nutritional supplement on a highly characteristic side effect of radiotherapy- weight loss.
• the effect of nutritional supplement of the inventive concept on loss of body mass and in particular muscle mass following repeated radiotherapy is shown in FIGs. 19A and 19B. It should be appreciated that body mass was characterized following removal of the tumor mass. It is apparent that pre-treatment with nutritional supplement of the inventive concept effectively prevents the loss of body mass (relative to control subjects) resulting from repeated radiotherapy.
• Another treatment protocol is shown in FIG. 20. A summary of the treatment groups generated by the protocol shown in FIG. 20 is provided in Table 6.
• FIG. 22 results of measurements of tumor volume during treatment of mice with the protocol shown in FIG. 20 are shown in FIG. 22.
• treatment with the nutritional supplement is effective in reducing the increase in tumor volume over time, particularly in combination with radiotherapy.
• the presence of tumors can also result in inflammation, which can be characterized by the presence of pro-inflammatory cytokines in serum.
• FIGs. 23 A and 23B show the effect of administration of nutritional supplement of the inventive concept with repeated radiotherapy on the concentration of pro-inflammatory cytokines in mice treated as in the protocol shown in FIG. 20.
• treatment with the nutritional supplement is effective in reducing the amount of pro-inflammatory cytokines found in serum of tumor-bearing animals, particularly in
• nutritional supplements of the inventive concept have been shown to be effective in enhancing the effects of radiotherapy and/or reducing the side effects of radiotherapy, Inventors contemplate that similar benefits are found when such nutritional supplements are used in combination with immunotherapies- particularly immunotherapies directed towards the treatment of cancer.
• immunotherapy in combination with use of a nutritional supplement of the inventive concept can be used in combination (e.g. either simultaneously or sequentially) with a radiotherapy.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Polymers & Plastics (AREA)
• Mycology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Pediatric Medicine (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Pathology (AREA)
• Radiology & Medical Imaging (AREA)
• Epidemiology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Jellies, Jams, And Syrups (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=61831274

Family Applications (1)

Country Status (9)

Cited By (7)

Families Citing this family (11)

Citations (6)

Family Cites Families (50)

• 2017
  • 2017-10-03 IL IL265786A patent/IL265786B/en unknown
  • 2017-10-03 CN CN201780074052.5A patent/CN110312439A/zh active Pending
  • 2017-10-03 CA CA3038327A patent/CA3038327C/en active Active
  • 2017-10-03 US US16/338,678 patent/US11206861B2/en active Active
  • 2017-10-03 CA CA3228010A patent/CA3228010C/en active Active
  • 2017-10-03 JP JP2019539733A patent/JP7123945B2/ja active Active
  • 2017-10-03 EP EP17859044.4A patent/EP3518689A4/en not_active Withdrawn
  • 2017-10-03 SG SG11201901501UA patent/SG11201901501UA/en unknown
  • 2017-10-03 WO PCT/US2017/054988 patent/WO2018067604A1/en not_active Ceased
  • 2017-10-03 KR KR1020197012627A patent/KR102402485B1/ko active Active
• 2021
  • 2021-12-08 US US17/545,864 patent/US12035739B2/en active Active
• 2022
  • 2022-08-10 JP JP2022127809A patent/JP7465313B2/ja active Active

Patent Citations (6)

Also Published As

Similar Documents

Legal Events